GenSight Biologics Announces First Half 2025 Financial Results

GenSight Biologics, a biopharmaceutical company, reduced its operating cash outflows by 8.3% in the first half of 2025. This reduction is the result of optimized financial resource management. Thanks to €3.7 million in financing, it extends its cash horizon to the end of 2025. Research and development expenses were reduced by 31.8%, amounting to €4.3 million.

As revenue declines, primarily due to accounting revaluations, the company is focusing on transferring production to Catalent, Inc. In parallel, a dose-ranging study protocol has been submitted to the ANSM, with a decision expected by the end of 2025.

GenSight's cash position stands at €0.3 million as of June 30, 2025. Despite these challenges, including a net loss of €7 million, the company anticipates non-dilutive revenues through the sale of licenses and early access programs.